Clinical Trial Update: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype [Phase 3]

View source ↗

Summary

A Phase 3 study of GSK3511294 (Depemokimab) in participants with severe eosinophilic asthma has been completed and results have been posted. The trial was spons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GSK3511294 (Depemokimab) (depemokimab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2024-11-29